Analysis Of Research Status of Antibody-Drug Conjugate in The Treatment of Colorectal Cancer

Shaoting Luo

doi:10.54097/xmck6m47

Authors

Shaoting Luo

DOI:

https://doi.org/10.54097/xmck6m47

Keywords:

Colorectal cancer, antibody-drug conjugate, clinical manifestations.

Abstract

As the most frequent malignant tumors in the digestive system, Colorectal Cancer (CRC) has a high incidence and mortality in recent years. Asymptomatic or asymptomatic symptoms are not obvious in CRC patients due to early clinical manifestations. The current treatment plan for CRC is a comprehensive treatment plan based on surgery, but about 30% of patients still have recurrence and metastasis and lead to death after receiving traditional treatment. The treatment of CRC is still being optimized, and more scientists are constantly investing in the discovery and development of novel medications. With the deepening of research and the improvement of clinical trial data, antibody-drug conjugate (ADC) targeting specific targets have gradually shown great potential therapeutic effects. In this paper, the basic principle of ADC, the research status of ADC for CRC and the application limitations of ADC drugs are reviewed. The development of ADC has brought new hope for the treatment of CRC patients, but the toxicity and drug resistance of ADC is still a great challenge to limit the efficacy of ADC. At present, how to combine ADC with personalized treatment of patients, effectively reduce toxicity, and find the next generation of high efficiency and low toxicity is the development direction of ADC.

Downloads

Download data is not yet available.

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: https://doi.org/10.3322/caac.21834

[2] Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol, 2021, 14(10): 101174. DOI: https://doi.org/10.1016/j.tranon.2021.101174

[3] Li Ruizhi, et al. Progress in traditional Chinese medicine treatment for colorectal cancer[J]. Haixia Pharmacy, 2014(12): 105-107.

[4] Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors[J]. Cancer Treat Rev, 2000, 26(4): 269-286. DOI: https://doi.org/10.1053/ctrv.2000.0176

[5] Natsume N, Sato H. Improving effects or functions of antibodies for cancer treatment: Enhancing ADCC and CDC[J]. Drug Devel Ther, 2009, 3: 7-16. DOI: https://doi.org/10.2147/DDDT.S4378

[6] Staudacher AH, Brown MP. Antibody-drug conjugates and bystander killing: Is antigen-dependent internalization required[J]. Br J Cancer, 2017, 117(12): 1736-1742. DOI: https://doi.org/10.1038/bjc.2017.367

[7] Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): A multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 779-789.

[8] Suwaidan AA, Lau DK, Chau I. HER2 targeted therapy in colorectal cancer: new horizons[J]. Cancer Treat Rev, 2022, 105: 102363. DOI: https://doi.org/10.1016/j.ctrv.2022.102363

[9] Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(6): 738-746. DOI: https://doi.org/10.1016/S1470-2045(16)00150-9

[10] Sartore-Bianchi A, Lonardi S, Martino C, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial[J]. ESMO Open, 2020, 5(5): e000911. DOI: https://doi.org/10.1136/esmoopen-2020-000911

[11] Nakamura Y, Okamoto W, Kato T, et al. TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study[C]. ESMO, 2019, Abstract 526PD. DOI: https://doi.org/10.1093/annonc/mdz246.004

[12] Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): A multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2023, 24(5): 496-508. DOI: https://doi.org/10.1016/S1470-2045(23)00150-X

[13] Strickler JH, Cercek A, Siena S, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2019, 20(4): 518-530. DOI: https://doi.org/10.1016/S1470-2045(18)30904-5

[14] Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): A multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 779-789. DOI: https://doi.org/10.1016/S1470-2045(21)00086-3

[15] Riccardi F, Dal Bom, Macor P, et al. A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy[J]. Frontiers in Pharmacology, 2023, 14: 1274088. DOI: https://doi.org/10.3389/fphar.2023.1274088

[16] Tarantino P, Ricciuti B, Pradhan SM, et al. Optimizing the safety of antibody-drug conjugates for patients with solid tumours[J]. Nature Reviews Clinical Oncology, 2023, 20(8): 558-576. DOI: https://doi.org/10.1038/s41571-023-00783-w

[17] Simmons JK, Burke PJ, Cochran JH, et al. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation[J]. Toxicol Appl Pharmacol, 2020, 392: 114932. DOI: https://doi.org/10.1016/j.taap.2020.114932

[18] Vermas B, Breadner D, Raphael J. "Targeting" improved outcomes with antibody-drug conjugates in non-small cell lung cancer: An updated review[J]. Curr Oncol, 2023, 30(4): 4329-4350. DOI: https://doi.org/10.3390/curroncol30040330